The Investment Column: British Biotech
Friday 19 November 1999
But the future still looks risky for British Biotech, if less so than previously. The company yesterday warned that crucial trial data for Marimastat in pancreatic cancer would be delayed a few weeks, and is due by February now.
Fortunately, this is for logistical reasons only, but the shares fell 8 per cent on the news. On the upside, a cost-reduction programme is nearly complete. Cash burn in the half year lessened from pounds 17m to pounds 12m, while pre-tax losses narrowed to pounds 11.4m from pounds 16.6m. The group still has pounds 86m of cash in its coffers.
While a partnership deal with Schering-Plough of the US is a vote of confidence in Marimastat, British Biotech is not relying on the drug.
It is in talks to acquire up to five new products, either through licensing deals or through straightforward acquisitions. Until news of these breaks, the shares, at 28.5p, are highly speculative.
- 1 Venezuela Expo Tattoo 2015: Extreme body art from 'Vampire Woman' to 109mm earlobes
- 3 Ball pool for adults opens in London
- 4 Game of Thrones season 5 trailer: The first full-length look is here
Boris Johnson claims porn-obsessed Islamic jihadists are 'literally w*****s'
Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
Putin opponent reveals Russian President's daughter's secret identity
Ball pool for adults opens in London
Amal Clooney gives excellent response to fashion question at European Court of Human Rights
9 reasons Greece's experiment with the radical left is doomed to failure
Have we reached 'peak food'? Shortages loom as global production rates slow
Greece elections: Syriza and EU on collision course after election win for left-wing party
British grandmother Lindsay Sandiford faces execution by firing squad in Indonesia
Liberal Democrat minister defends comments suggesting immigration causes pub closures
King Abdullah dead: We can't afford not to hold Saudi Arabia's royals to account
iJobs Money & Business
£40000 - £50000 per annum: Recruitment Genius: This is an exciting opportunity...
£30000 - £35000 per annum + Benefits: Ashdown Group: Marketing Manager - Marke...
£13000 per annum: Recruitment Genius: This Pension Specialist was established ...
£23000 - £26000 per annum + Benefits: Ashdown Group: Market Research Executive...